MODULATION OF LC3-ASSOCIATED ENDOCYTOSIS PATHWAY AND GENETICALLY MODIFIED NON-HUMAN ANIMALS AS A MODEL OF NEUROINFLAMMATION AND NEURODEGENERATION
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Apr 7, 2022
app pub date -
Jan 22, 2020
filing date -
Jan 22, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Compositions and methods are provided for modifying and treating neuroinflammatory and neurodegenerative diseases. The methods and compositions can be used to ameliorate the effects of a deficiency in the LC3-associated endocytosis (LANDO) pathway for clearing β-amyloid. Thus, methods are further provided for modulating β-amyloid clearance using an effective amount of a pharmaceutical composition that targets the LANDO pathway. Accordingly, pharmaceutical compositions that target the LANDO pathway are provided herein. The methods and compositions described herein can be used to treat neuroinflammatory and neurodegenerative diseases, such as Alzheimer's disease.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully